for prostate cancer is relatively good, with 5.8% of cancer deaths in men being attributed to prostate cancer (Parkin et al., 2005) . Prostate cancer has a 5-year disease-specific survival of 56.6% and overall survival of 38% (National Cancer Registry Ireland, 2004) . Low Gleason scores, clinical staging, and tumor aggressiveness on diagnosis predict increased survival in men with prostate cancer. Improved availability of global transportation and communication has afforded the health care community the unprecedented opportunity to understand the most current worldwide knowledge regarding diseases such as prostate cancer. Consequently, health care providers have the opportunity to learn about the health concerns of other countries with similar problems. A description of uncertainty and quality of life (QOL) among men with prostate cancer in samples from P rostate cancer continues to be the most common site of male cancers, particularly among older men in Europe and the United States, and the second most common male cancer worldwide (Parkin, Bray, Ferlay, & Pisani, 2005) . Prostate cancer accounts for approximately 21% of all male cancers and 7% of cancer deaths in Ireland (National Cancer Registry Ireland, 2005) . The disease occurs mostly in men over the age of 65 (National Cancer Registry Ireland, 2004; Parkin et al., 2005) . Prognosis
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Background. Prostate cancer continues to be the most common site of male cancers, particularly among older men in Europe and the United States, and the second most common male cancer worldwide. Active surveillance involves the use of no local or systemic therapy once prostate cancer has been diagnosed. A description of uncertainty and quality of life among men undergoing active surveillance in samples from both the United States and Ireland has the potential to enhance global health care delivery. Methods. The specific aim of this study is to enhance the understanding of the experience of active surveillance for prostate cancer among Irish and American men by measuring quality of life and levels of uncertainty among men over the age of 65 in receipt of the active surveillance management option for prostate cancer. A quantitative, descriptive survey design was used. Results. Twenty-nine men completed questionnaires. The results reveal that men undergoing active surveillance in the United States have slightly higher levels of uncertainty. Primary appraisal, opportunity, and danger appraisal were consistent between samples from both countries. Total affective and health-related qualityof-life scores were similar among active surveillance participants in both countries, but subscale scores identified both similarities and differences. Irish men had lower mean role and social function than U.S. men, and higher general health and energy. Irish men reported more urine bother and less sexual bother than U.S. men. Conclusion. To assist men with prostate cancer who are treated with the active surveillance management option, health care professionals must develop an awareness of how prostate cancer affects the man's physical and psychological health care outcomes.
both countries has the potential to enhance global health care delivery. The purpose of this study is to explore uncertainty and QOL of American and Irish men over the age of 65 undergoing the active surveillance management strategy for prostate cancer.
Background
The combination of diagnostic screening techniques such as digital rectal examination, prostate specific antigen (PSA) assay, and transrectal ultrasound examination has substantially increased the efficiency of detecting early-stage prostate cancer. Screening programs have permitted the early detection of prostate cancer in asymptomatic men who might have died of other causes before their prostate cancer became clinically relevant. Since PSA detection commenced, there has been a marked decrease in the rate of newly diagnosed distant (Stage IV) prostate cancer (Parkin et al., 2005) with a steep rise in the early detection of clinically localized disease. The estimation of lead time between diagnosis using PSA screening and development of clinical symptoms varies, with one Finnish randomized controlled trial estimating a lead time of 5 to 7 years (Auvinen et al., 2002) . Many factors influence the lead time-particularly age, sensitivity of screening tests, and rate of tumor development, with shorter lead times for more aggressive tumors (Schröder, de Vries, & Bangma, 2003) .
Treatment for clinically localized prostate cancer consists of interventions with curative intent-surgery (radical prostatectomy, cryosurgery), radiation therapy (external beam radiation and brachytherapy), and interventions with palliative intent (androgen deprivation therapy, chemotherapy, and hormonal treatment). The reality is that the majority of men with localized disease are offered curative treatments (surgery and radiotherapy) (Krupski, Kwan, Afifi, & Litwin, 2005; National Cancer Registry Ireland, 2004) despite the fact that it may be unnecessary (Klotz & Nam, 2006) . This raises the question of whether aggressive treatment of newly detected prostate cancer affects longevity and QOL.
Active surveillance or watchful waiting encompasses a variety of conservative "watch and wait" approaches to the management of prostate cancer whereby a decision is made to monitor the patient and to defer any form of therapy such as surgery, radiation therapy, or hormone therapy until such time as the monitoring procedure documents local progression or distant dissemination. Advocates of active surveillance contrast the slow-growing indolent nature of prostate cancer with the potential side effects of therapy. Active surveillance can be understood to be initial surveillance followed by active treatment if and when the cancer becomes symptomatic (Adolfsson, 1995; Klotz & Nam, 2006) . Other terms used in the literature include observation, watchful waiting, conservative management, and expectant management (Albertsen, Hanley, Gleason, & Barry, 1998; Bill-Axelson et al., 2005) . Active surveillance is usually only considered suitable for patients with clinically localized intracapsular low-grade prostate cancer (Aus et al., 2005) . Hardie et al. (2005) reported on the early outcomes of active surveillance for 80 men with localized prostate cancer. The researchers noted that at a median followup of 42 months, 80% of the men remained under observation, 14% received radical treatment, and 5 had died of other causes. Early work by Fowler et al. (1998) reported that only 3% of urologists in the United States consider a conservative approach (watchful waiting) to be as appropriate as radical prostatectomy or radiation for prostate cancer. More recent statistics indicate that only 8.4% of U.S. men with prostate cancer undergo observation (Yan, Carvalhal, Catalona, & Young, 2000) , and the National Cancer Data Base (2003) in the United States found that approximately 9% of men have no primary course of treatment for their prostate cancer. The majority of Irish men (77%) received some form of treatment for their prostate cancer, leaving the remaining 23% to watch and wait (National Cancer Registry Ireland, 2005) . The discrepancy in the number of untreated men in samples from both countries may be a product of both improved treatment access and reimbursement for treatments in the United States.
Factors considered when choosing treatment for prostate cancer are varied and include the patient's belief about the therapy's intrinsic characteristics, supporting evidence, and patterns of complications. In Holmboe and Concato's (2000) , 102 men with newly diagnosed localized prostate cancer were posed openended questions about the factors influencing their treatment choices. Ninety men chose to reject a watchful waiting observation protocol because of fear of future consequences including the need to combat the tumor (58%, n = 64), the need to do something, and fear of tumor spread. Thus, some men appear to be uncomfortable living with the uncertain risk associated with cancer (Holmboe & Concato, 2000) . Uncertainty has been determined to be a predictor of QOL in men undergoing active surveillance for prostate cancer (Wallace, 2003) .
Uncertainty
Uncertainty is defined as the "inability to determine the meaning of illness-related events which occurs in situations where the decision maker is unable to assign definite values to objects and events and/or is unable to accurately predict outcomes because sufficient cues are lacking" (Mishel, 1988, p. 225) . Uncertainty is a psychological stressor that can be associated with most illness experiences, particularly cancer. Mishel (1988) described uncertainty as an inability to determine the meaning of illness-related events; uncertainty is associated with an inability to predict outcomes accurately. This is particularly relevant to the men undertaking the active surveillance management option for prostate cancer, where uncertainty may be associated with living with preexisting disease, the possibility of disease progression, the uncertainty associated with waiting for the results of observation protocols and future prognosis. Living with an illness such as cancer may be complex, unpredictable, vague, ambiguous, and unfamiliar (McCormick, 2002) . Emotional distress, anxiety, and depression occur because of a stressor such as uncertainty (Dale, 2005; McCormick, 2002) . Consistent with most descriptions of uncertainty and threat is the concept of appraisal. When a threatening event occurs, individuals first decide if the event is irrelevant, positive, or threatening. This is termed primary appraisal. The individual then assesses his ability to meet the challenge or combat the threat; this is termed secondary appraisal. Men diagnosed with prostate cancer may view the diagnosis as a threat to their lives. However, Ahmad (2005) reported that men with prostate cancer (N = 133) identified threat appraisal with less frequency than appraisals of harm/loss or challenge.
Quality of Life
The concept of QOL is very important to all people whether diagnosed with cancer or not. Quality of life is a multidimensional concept, which captures the subjective feelings of well-being of patients in the physical, psychological, and social arena including such attributes as positive social involvement and opportunities to achieve personal potential (Hacker, 2003; Zebrack, 2000) .
Quality of life in men with prostate cancer is heavily influenced by both uncertainty and functional variables, such as urinary, bowel, and sexual function. In a cross-sectional comparative study, QOL was evaluated in patients (n = 32) 12 months after prostatectomy and compared to men presurgery (n = 28). Men who underwent surgery reported a significant deterioration in sexual function and dissatisfaction with their postoperative sexual functioning (Arai et al., 1999) . Livsey et al. (2002) examined the subjective late effects of radiotherapy for prostate cancer on the reported bowel, bladder, and sexual function in 101 randomly selected men (mean age 71, range 54-83) at least 3 years post radical radiotherapy for prostate cancer. The men completed the University of California-Los Angeles Prostate Cancer Index UCLA-PCI, the Medical Outcomes Study 36-Item Short Form (SF-36), and the LENT/SOMA questionnaire. UCLA urinary bother scored a mean of 82 on a scale of 0 to 100 (where 0 was the worst function and 100 was the best). Urine function was reported at 88, and sexual function and bother scored a mean of 24 and 60, respectively. Greene et al. (2005) described the average newly diagnosed man with prostate cancer using data gathered during the Cancer of the Prostate Strategic Urologic Research Endeavour (CaPSURE) study. The researchers identified 3,003 men diagnosed with prostate cancer between 1997 and 2003 from the CaPSURE database; all men completed the UCLA-PCI and the SF-36. Pretreatment urine bother scored 82 and 85, and urine function scored 93 and 92. Patients reported average or above average pretreatment results on the QOL scales chosen.
A Swedish randomized controlled trial conducted by Steineck et al. (2002) , which compared radical prostatectomy with watchful waiting as a treatment option among 326 men, demonstrated that erectile dysfunction (80% vs. 45%) and urinary leakage (49% vs. 21%) were more common 4 years after surgery, whereas urinary obstruction was less common (Steineck et al., 2002) . Urinary obstruction in such patients would require further intervention such as insertion of a catheter, transurethral resection of prostate, or nephrostomy tube insertion, whereas erectile dysfunction (decreased frequency of intercourse and orgasm) and urinary leakage are very distressing for men of any age. Subjective QOL was assessed using a 7-point visual digital scale. Steineck et al. concluded that the subjective QOL was similar in the two groups: The values for low to moderate subjective QOL were 40% (prostatectomy group) versus 45% (watchful waiting group). Arredondo et al. (2004) reported on health-related quality of life (HRQoL) in 310 men with localized prostate cancer who selected watchful waiting within the Cancer of the Prostate Strategic Urological Research Endeavour. The UCLA-PCI, including the RAND 36-Item Health Survey, was completed at enrollment and approximately every 6 months for up to 5 years after diagnosis. Significant decreases with time were observed in the seven domains of the RAND survey and four of the UCLA prostate cancer scales, and similar HRQOL outcomes were reported in the watchful waiting group compared to a control group of men without prostate cancer. In their study, notable changes in the physical domain and sexual function scores were attributed to the aging process alone.
Methods
This study used a quantitative, descriptive design. Approval for this study was obtained from the Irish College of General Practitioners Ethical Approval Board, New York University Committee on Activities Involving Human Subjects, and Southern Connecticut State University Institutional Review Board.
Sample
Based on the common convention of "number of observations" (n) divided by the "number of variables" (v) must be greater than or equal to 10 (Knapp & Campbell-Heider, 1989, p. 634 ), a minimum sample size of 50 participants from each country was identified as the necessary sample size for this study (50 (n) / 5 (v); uncertainty, anxiety, primary appraisal, HRQOL, and affective QOL, ≥ 10). However, recruitment efforts resulted in a total convenience sample of only 29 men undergoing active surveillance for prostate cancer in southern Ireland (n = 10) and the United States (n = 19). Inclusion criteria limited involvement in the study to men over the age of 65, with a confirmed diagnosis of prostate cancer by biopsy, who were in receipt of no active treatment for their disease, and who were aware of their diagnosis and competent to complete a questionnaire or to be interviewed (if they wished). Irish prostate cancer participants were recruited with the assistance of the National Cancer Registry Ireland (NCRI) and patient family physicians. Letters were sent from the NCRI to the patient's family physician, the inclusion criteria and the patient's suitability to partake in the study were reassessed, and questionnaires were sent to suitable patients by the family physician inviting them to partake in the study. The researcher only became aware of the patient identity when the consent form was returned with the questionnaire. The NCRI sent out one reminder to family physicians regarding their participation in the study. American men (n = 19) responded to advertisements or were recruited with the assistance of American urologists. The subject recruitment flyer was also posted on eight prostate cancer Web sites and distributed at local supermarkets and libraries, and an advertisement was placed in the Healthy Living section of the New York Times. Expansive efforts and expense were put forth in recruiting for this study but resulted in a discrepancy in the number of participants targeted versus the number obtained.
Data Collection Method
When the participants consented to participate in the study, they completed a self-administered questionnaire and returned it to the nurse researcher or contacted the researcher who interviewed them at a location of their choice. In Ireland, 92 patient questionnaires were sent to Irish family physicians (in two mailings), of which 58 questionnaires were returned. Eight were complete, 2 partially complete, 2 men agreed to be interviewed when questionnaires were completed by the researcher, 6 men had died, 11 men had commenced treatment, 20 patients were deemed unfit by the family physician to complete the questionnaires, and 9 questionnaires were returned uncompleted by the men themselves. In the United States, flyers along with an accompanying letter were mailed to 4,500 urologists identified through a purchased database from the American Urological Association, representing diverse geographical areas throughout the United States ( ). Twenty-one men called the tollfree number requesting to participate in the study. Nineteen of these individuals met the criteria and returned the questionnaire. Patients self-completed questionnaires in the United States and Ireland (n = 27) or were interviewed by the researcher in Ireland only (n = 2). Poor response rates may reflect the low number of men undergoing active surveillance in each country as well as participants' decreased involvement with health care providers who recruited for this study.
Instruments
Information was gathered on the dependent variables uncertainty, appraisal, and QOL. A researcherdeveloped personal demographic data form was used to gather information pertaining to the patient's age, length of time since diagnosis with prostate cancer, education levels, martial or relationship status, socioeconomic status, and medical history. The Mishel Uncertainty in Illness Scale− Community form (MUIS-C) (Mishel, 1997) comprised of a 23-item 5-point Likert-type scale, was used to measure uncertainty in the study. The MUIS has been tested in several populations resulting in a total alpha reliability reported for the scale in each of these populations ranging from .74 to .95. Content validity has been supported through expert analysis of the items during the development of the MUIS. Construct validity for the MUIS was supported through a factor analysis indicating a fourfactor structure (Mishel, 1997) : ambiguity (13 items), complexity (7 items), inconsistency (7 items), and unpredictability (5 items) (Mishel, 1997) . The Folkman and Lazarus Appraisal scale (1985) measured primary appraisal including the subcategories of danger (harm) and opportunity (challenge). A two-factor structure consisting of opportunity and danger resulted from factor analysis testing. The total explained variance of the scale by the two factors was 50.1%. The first factor contains eight items that address danger, and the second factor contains seven items that measure opportunity. Higher scores on each subscale indicate greater opportunity or greater danger. Because of the polarized nature of the two concepts measured, the Opportunity and Danger subscales within this study showed an expected, low internal consistency reliability between α = .38 and .39.
The personal nature of QOL and the great variability inherent in individual values make defining the concept difficult. It is generally accepted that function is primarily an objective measure of QOL, whereas well-being is usually subjective. Function is primarily measured as health-related QOL, and well-being is generally evaluated with affective measures of the concept. This study approached the measurement of QOL by measuring function, using an HRQOL measure and well-being using an affective measure of QOL. The Power (1985, 1992) Quality of Life Index (QLI) Cancer Version as an affective QOL measure asked participants to rate their satisfaction with, and importance of, 34 different items corresponding to important health and life domains. Criterion-related, concurrent validity was assessed by comparing the result of the QLI with a uniscale measurement of QOL. Results revealed moderately high correlations between the two instruments in two groups (r = .75 for graduate students; r = .65 for hemodialysis patients). Test-retest reliability revealed high correlations (r = .87) at 2 weeks for graduate students and dialysis patients (r = .81) 1 month later. The significance of the correlations was not reported. Internal consistency is reported at α = .93 for graduate students and α = .90 for dialysis patients.
The UCLA-PCI included the SF-36v2 (Litwin et al., 1998) . This is a widely validated scale that measures six domains of prostate cancer-related QOL: urinary function, urinary bother, bowel function, bowel bother, sexual function, and sexual bother. Each item is scored from 0 to 100, with higher scores representing better HRQOL. A factor analysis of the entire UCLA-PCI was conducted with a sample of 523 men. Of the sample, 255 were survivors of prostate cancer and 273 were healthy men without prostate cancer. The factor analysis revealed a six-factor scale including urinary function (5 items), bowel function (4 items), sexual function (8 items), urinary bother (1 item), bowel bother (1 item), and sexual bother (1 item). Test-retest reliability ranged from r = .53 to .93. Internal consistency reliability ranged from α = .64 to .93 for the 11 multi-item scales in the instrument (eight scales from the original SF-36 and three additional, multiitem scales from the disease-specific module).
Cronbach's alpha scores for the questionnaires used in this study are revealed in Table 1 .
Results
The Irish sample for this analysis consisted of 10 men undergoing active surveillence for prostate cancer in the South of Ireland (Cork and Kerry). The U.S. sample consisted of 19 men undergoing active surveillance in the states of Arizona (1), California (2), Connecticut (1), Florida (11), New Hampshire (1), New York (2), and Texas (1). The data revealed that some demographic characteristics of the sample were similar between the United States and Ireland, including average age and income. However, Irish men had fewer medical conditions per participant and less education. The Irish sample appears to have a longer period of time with the disease. However, this may be explained by the larger U.S. sample and the presence of several U.S. participants who had long periods of time with the disease. Information regarding the demographic characteristics of the sample is revealed in Table 2 .
Due to the low sample size in this study, only descriptive statistics were computed for the independent variables: uncertainty, total primary appraisal score, danger appraisal, and opportunity appraisal. The data revealed that primary appraisal, opportunity, and danger appraisal were fairly consistent between samples from both countries. Moreover, the U.S. sample experienced slightly higher uncertainty than those in Ireland. The means, standard deviations, and range of scores for both samples are reported in Table 3 .
Affective and health-related total scores were similar among participants in both samples from both countries, but subscale scores showed both similarities and differences. Irish men had a lower mean role function and social function than U.S. men and higher general health and energy. Irish men also reported more urine bother and less sexual bother than U.S. men. The U.S. sample scored less on vitality and their perception of general health. In contrast, the Irish men seemed to be less uncertain, had more role limitations, and had lower social functioning. The means, standard deviations, total scores, and subscale measures of health-related and affective QOL (Ferrans and Power QLI and the UCLA-PCI) are shown in Tables 4 and 5, respectively.
Discussion
The purpose of this study was to describe uncertainty, primary appraisal, and QOL of Irish and U.S. Primary appraisal, opportunity, and danger appraisal were fairly consistent between samples from both countries. These results are consistent with the work of Ahmad (2005) who studied 133 men with prostate cancer. The researcher identified threat (referring to anticipated harm or loss) appraisal with less frequency than appraisals of harm/loss (damage already experienced from the illness) or challenge (the appraisal provides an opportunity for growth, mastery, or gain). A rationale for this result may be that high survival rates and long survival time for patients with prostate cancer make living with this particular cancer appear less threatening than living with other types of cancer.
Although parametric statistics were not used related to the small sample size, the results revealed that men in the United States may experience slightly higher uncertainty than those in Ireland. There are a number of possible explanations for this minor discrepancy. In the United States, there may be a higher expectation for more active treatment than in Ireland. This is supported by Fowler et al. (1998) who report that only 3% of urologists in the United States consider watchful waiting to be as appropriate as radical prostatectomy or radiation for prostate cancer. Furthermore, a recent study found that only Uncertainty and Quality of Life / Hegarty et al. 139 (Yan et al., 2000) . Similarly, the National Cancer Data Base (2003) found that 8.66% of men had no primary course of treatment for their prostate cancer. Conversely, the majority of Irish men (77%) received some form of treatment for their prostate cancer during the period 1994 to 1998 (National Cancer Registry Ireland, 2005), leaving 23% untreated. Affective and health-related total scores appear similar among participants in samples from both countries, but subscale scores showed both similarities and differences. Irish men had a lower mean role function and social function than U.S. men, and higher general health and energy. Irish men also reported more urine bother and less sexual bother than U.S. men. In light of the small sample size, these differences should not be overinterpreted. Small differences may lie in the disparity between health care access between samples from both countries and available services to treat symptoms of prostate cancer, or they may lie within cultural differences. For example, greater awareness of geriatric sexuality among health care providers and the high availability of oral erectile agents in the United States may have resulted in less sexual bother in this population as opposed to Ireland.
Results obtained in this study for the SF-36 questionnaire appear comparable to results obtained by Arredondo et al. (2004) in 310 men with localized prostate cancer managed with a conservative watchful waiting approach. Significant decreases with time were observed in seven domains of the RAND 36-Item Health Survey, and four of the UCLA-PCI scales and similar HRQOL outcomes were reported in the watchful waiting group compared to a control group of men without prostate cancer. Notably, changes in the physical domain scores as well as sexual function scores were attributed to the aging process alone.
Older adult cancer survivors experience more health-related problems than older adults in general, with prostate cancer survivors more likely to report urinary and bowel incontinence (Deimling, Sterns, Bowman, & Kahana, 2005; Wei et al., 2002) . Irish and U.S. urine bother scores and urine function scores were slightly lower than some of the pretreatment results reported by Greene et al. (2005) in the CaPSURE study of 3,003 men with prostate cancer. Urine bother scored between 82 and 85 and urine function scored between 92 and 93. Livsey et al. (2002) reported on urine bother and urine function in men (mean age 71, range 54-83) at least 3 years post radical radiotherapy for prostate cancer. Urinary bother scored a mean of 82, and urine function was reported at 88, results that are comparable to the results of this study.
Sexual function scored a mean of 41.3 (U.S.) and 38.5 (Irish), and sexual bother scored 65.3 (U.S.) and 46.9 (Irish). Among samples from both countries, these scores are low and lower than mean scores obtained in Greene et al.'s (2005) study where sexual function scored a pretreatment value of 50 and 51 and sexual bother scored 60. In contrast, Livsey et al.'s (2002) 3 year posttreatment mean scores were lower for sexual function and comparable for sexual bother. Altered sexual bother and function is a feature of many research studies both with patients undertaking conservative treatment and proactive treatments. What is notable is that few men seek treatment for sexual-related concerns (Galbraith, Arechiga, Ramirez, & Pedro, 2005) .
Conclusions, Limitations, and Implications
This study provides information on the experience of active surveillance for prostate cancer among both Irish and U.S. men to enhance health care providers' understanding of the impact of living with prostate cancer. Health care providers in many settings are in an ideal position to support and advise men regarding the symptoms of their illness and management strategies, whereas urology or oncology specialists could provide support and/or interventions using the telephone of Web as the means of contact. To assist men with prostate cancer, health care providers must develop an awareness of how prostate cancer affects the man's appraisal of his situation.
This study was limited by a descriptive model and a small convenience sample. Clearly, these factors limit the generalizability of this study. Curative treatments for prostate cancer appears to be the favored treatment option for prostate cancer. This was evident in this study and needs to be examined closely in future research. Difficulty in participant recruitment is widely experienced among researchers interested in active surveillance and adds to the lack of understanding of the experience of men undergoing this management option. However, the results of this study may help health care professionals better understand the effect of active surveillance on men and plan appropriate health care interventions to support men being managed by active surveillance. Further research in the management strategies for men treated using active surveillance must be conducted in both the United States and Ireland for men undergoing this important management option for prostate cancer to experience the highest possible quality of life.
